Inibidores da monoaminoxidase e cetamina intravenosa: uma associação segura?

Autores

  • Juliana Machado Leal dos Santos Médica Residente do Programa de Residência Médica em Psiquiatria pela Secretaria de Saúde do Recife https://orcid.org/0000-0002-9759-1542
  • Hugo Leonardo de Oliveira Couto Médico Psiquiatra da Secretaria de Saúde do Recife, PE, Brasil https://orcid.org/0000-0002-1868-9817
  • Dennison Carreiro Monteiro Doutorando em Neuropsiquiatria e Ciências do Comportamento da Universidade Federal de Pernambuco https://orcid.org/0000-0002-3672-9894

DOI:

https://doi.org/10.25118/2763-9037.2022.v12.219

Palavras-chave:

segurança, inibidores da monoaminoxidase, cetamina, pressão sanguínea

Resumo

Introdução: A Cetamina emerge como uma droga rápida e efetiva no tratamento da Depressão Resistente ao Tratamento (DRT) e é a primeira droga com mecanismo de ação fora do sistema monoaminérgico aprovada para tal finalidade. Os pacientes com DRT, com frequência, estarão em uso, ou terão indicação de inibidores da monoaminoxidase (IMAOs). A cetamina tem efeitos simpaticomiméticos através, dentre outros mecanismos, de inibição da recaptura de noradrenalina; os riscos do uso concomitante dos IMAOs e de algumas drogas noradranérgicas já é estabelecido. Diante disto, a possibilidade de crises hipertensivas resultantes da combinação destes medicamentos requer atenção clínica. Objetivo: O objetivo desta revisão foi verificar aspectos importantes a respeito desta combinação, com enfoque na ocorrência de crises hipertensivas e outros efeitos cardiovasculares. Método: O estudo foi realizado através das bases de dados Pubmed, Scielo e Lilacs, datadas de 1990 até março de 2021, utilizando-se a combinação dos descritores: (Monoamine oxidase inhibitor) AND (Ketamine). Resultado: Os resultados demonstram segurança e eficácia da combinação, com elevações transitórias da frequência cardíaca e pressão arterial, sem consequências para os pacientes. Conclusão: Entretanto, tratam-se de dados de relatos e séries de casos e de uma pequena coorte retrospectiva. Portanto é possível que efeitos colaterais graves não sejam detectados nestas amostras por serem reduzidas.

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...

Referências

Lacerda AL, Del Porto JA. Uso da cetamina no tratamento de transtornos psiquiátricos e dor crônica: teoria e prática. São Paulo: Editora dos editores; 2020.

Zhou YL, Liu WJ, Wang CY, Zheng W, Lan XF, Weng SY, Ning YP. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. Journal of Psychopharmacology. 2021;35(2):159-167 https://doi.org/10.1177/0269881120936909

Liebe T, Shijia Li, Lord A, Colic L, Krause AL, Batra A, Kretzschmar MA, Sweeney-Reed CM, Behnisch G, Schott BH, Walter M. Factors influencing the cardiovascular response to subanesthetic ketamine: a randomized, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2017;20(11):909–918 https://doi.org/10.1093/ijnp/pyx055

Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ. Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. International Journal of Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. https://doi.org/10.1093/ijnp/pyab039 - PMid:34170315 - PMCid:PMC8538895

Muntner N, Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge: Cambridge University Press; 2013. 620 p.

McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate Jr. CA, Stahl S. Synthesizing the evidence for Ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. American Journal of Psychiatry. 2021;178(5):383-99. https://doi.org/10.1176/appi.ajp.2020.20081251 PMid:33726522

Gaynes BN, Lux L, Gartlehner G, Asher G, Forman‐Hoffman V, Green J, Boland E, Weber RP, Randolph C, Bann C, Coker‐Schwimmer E, Viswanathan M, Lohr KN. Defining treatment‐resistant depression. Depression and Anxiety. 2019;37(2):134-45. https://doi.org/10.1002/da.22968 PMid:31638723

Murphy JA, Sarris J, Byrne GJ. A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depression Research and Treatment. 2017:1-10. https://doi.org/10.1155/2017/4176825 - PMid:28840042 - PMCid:PMC5559917

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. 2006;163(11):1905-17. https://doi.org/10.1176/ajp.2006.163.11.1905 PMid:17074942

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A consensus statement on the use of ketamine in the treatment of Mood disorders. JAMA Psychiatry. 2017;74(4):399. https://doi.org/10.1001/jamapsychiatry.2017.0080 PMid:28249076

Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. The Journal of Clinical Psychiatry. 2018;79(4). https://doi.org/10.4088/jcp.17m11731 - PMid:30063304 PMCid:PMC6296748

Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. American Journal of Psychiatry. 2017;174(7):695-696. https://doi.org/10.1176/appi.ajp.2017.17020239 - PMid:28669202 PMCid:PMC5549850

Giakoumatos CI, Osser D. The Psychopharmacology Algorithm Project at the Harvard South Shore Program. Harvard Review of Psychiatry. 2019;27(1):33-52. https://doi.org/10.1097/hrp.0000000000000197 PMid:30614886

Veraart JKE, Smith-Apeldoorn SY, Spaans HP, Kamphuis J, Schoevers RA. Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. J Affect Disord. 2021;281:82-89. https://doi.org/10.1016/j.jad.2020.11.123 PMid:33307338

McIntyre RS, Carvalho IP, Lui LM, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Yena L, Tamura JK, Iacobucci M, Lee P, Nasri F, Singhal N, Wong ER, Subramaniapillai M, Mansur R, Ho R, Lam RW, Rosenblat JD. The effect of intravenous, intranasal, and oral ketamine in Mood disorders: a meta-analysis. Journal of Affective Disorders. 2020;276:576-84. https://doi.org/10.1016/j.jad.2020.06.050 PMid:32871689

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry. 2018;175(2):150-8. https://doi.org/10.1176/appi.ajp.2017.17040472 PMid:28969441 PMCid:PMC5794524

Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M. Efficacy of eketamine augmentation in major depressive disorder. The Journal of Clinical Psychiatry. 2020;81(4). https://doi.org/10.4088/jcp.19r12889

Culpepper L. Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy. Prim Care Companion CNS Disord. 2013;81. https://doi.org/10.4088/PCC.13r01515

Hopia H, Latvala E, Liimatainen L. Reviewing the methodology of an integrative review. Scandinavian Journal of Caring Sciences. 2016;30(4):662-9. https://doi.org/10.1111/scs.12327 - PMid:27074869

Whittemore R, Knafl K. The integrative review: updated methodology. Journal of Advanced Nursing. 2005;52(5):546-53. https://doi.org/10.1111/j.1365-2648.2005.03621.x - PMid:16268861

Katz RB, Toprak M, Wilkinson ST, Sanacora G, Ostroff R. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: a letter to the editor. General Hospital Psychiatry. 2018;54:62-4. https://doi.org/10.1016/j.genhosppsych.2018.05.007 PMid:30100209 - PMCid:PMC6292194

Dunner DL. Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report. Neurology Psychiatry and Brain Research. 2020; 36:30-31. https://doi.org/10.1016/j.npbr.2020.02.008

Doyle DJ. Ketamine induction and monoamine oxidase inhibitors. Journal of Clinical Anesthesia. 1990;2(5):324-5. Disponível em: https://doi.org/10.1016/0952-8180(90)90078-h

Bartova L, Vogl SE, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, Willeit M. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. European Neuropsychopharmacology. 2015;25(11):2183-4. https://doi.org/10.1016/j.euroneuro.2015.07.021 - PMid:26302763

Wang JC, Swainson J. The concurrent treatment with intravenous ketamine and an irreversible monoamine oxidase inhibitor for Treatment-Resistant Depression without hypertensive crises. Journal of Clinical Psychopharmacology. 2020;40(5):515-7. https://doi.org/10.1097/JCP.0000000000001244 - PMid:32740556

Bottemanne H, Bonnard E, Claret A, Petit AC, Gaillard R, Fossati P. Ketamine and monoamine oxidase inhibitor combination. Journal of Clinical Psychopharmacology. 2020;40(6):636-8. https://doi.org/10.1097/JCP.0000000000001281 - PMid:33009225

Lu BY, Agapoff JR, Olson DJ, Williams SR, Roller A, Goebert D. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: a case series. Journal of Affective Disorders. 2020; 262:40-42. https://doi.org/10.1016/j.jad.2019.10.050

Ludwig VM, Sauer C, Young AH, Rucker J, Bauer M, Findeis H, Ritter P. Cardiovascular effects of combining subcutaneous or intravenous esketamine and the MAO inhibitor tranylcypromine for the treatment of depression: a retrospective cohort study. CNS Drugs. 2021; 35:881-892. https://doi.org/10.1007/s40263-021-00837-6

Riva-Posse P, Reiff CM, Edwards JA, Job GP, Galendez GC, Garlow SJ, Saah TC, Dunlop BW, McDonald WM. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. Journal of Affective Disorders. 2018;236,291–297. https://doi.org/10.1016/j.jad.2018.02.025

van Haelst IMM, van Klei WA, Doodeman HJ, Kalkman CJ, Egberts TCG, MAOI Study Group. Antidepressive treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. The Journal of Clinical Psychiatry. 2012;73(8):1103-1109. https://doi.org/10.4088/jcp.11m07607 - PMID: 22938842

Downloads

Publicado

2022-07-01

Como Citar

1.
Santos JML dos, Couto HL de O, Monteiro DC. Inibidores da monoaminoxidase e cetamina intravenosa: uma associação segura?. Debates em Psiquiatria [Internet]. 1º de julho de 2022 [citado 14º de agosto de 2022];12:1-20. Disponível em: https://revistardp.org.br/revista/article/view/219

Edição

Seção

Artigos de Revisão